HK1042244A1 - 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物 - Google Patents

包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物 Download PDF

Info

Publication number
HK1042244A1
HK1042244A1 HK02104004.4A HK02104004A HK1042244A1 HK 1042244 A1 HK1042244 A1 HK 1042244A1 HK 02104004 A HK02104004 A HK 02104004A HK 1042244 A1 HK1042244 A1 HK 1042244A1
Authority
HK
Hong Kong
Prior art keywords
nsaid
colorectal cancer
kinase inhibitor
inhibition
treatment
Prior art date
Application number
HK02104004.4A
Other languages
English (en)
Chinese (zh)
Inventor
Frost Philip
Mary Discafani-Marro Carolyn
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of HK1042244A1 publication Critical patent/HK1042244A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02104004.4A 1999-08-12 2000-08-02 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物 HK1042244A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
US09/373,261 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (1)

Publication Number Publication Date
HK1042244A1 true HK1042244A1 (zh) 2002-08-09

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104004.4A HK1042244A1 (zh) 1999-08-12 2000-08-02 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物

Country Status (24)

Country Link
EP (1) EP1202746B1 (enExample)
JP (1) JP2003507342A (enExample)
KR (1) KR20020018201A (enExample)
CN (1) CN1229142C (enExample)
AR (1) AR029763A1 (enExample)
AT (1) ATE341341T1 (enExample)
AU (1) AU783116B2 (enExample)
BR (1) BR0013219A (enExample)
CA (1) CA2380904C (enExample)
CZ (1) CZ2002474A3 (enExample)
DE (1) DE60031127T2 (enExample)
DK (1) DK1202746T3 (enExample)
EA (1) EA006876B1 (enExample)
ES (1) ES2272305T3 (enExample)
HK (1) HK1042244A1 (enExample)
HU (1) HUP0203162A3 (enExample)
IL (1) IL147913A0 (enExample)
MX (1) MXPA02001448A (enExample)
NO (1) NO20020663L (enExample)
NZ (1) NZ517120A (enExample)
PL (1) PL353267A1 (enExample)
PT (1) PT1202746E (enExample)
WO (1) WO2001012227A1 (enExample)
ZA (1) ZA200201156B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
EP1409481B1 (en) 2001-07-16 2006-10-04 Astrazeneca AB Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
EP1758601A1 (en) 2004-06-03 2007-03-07 F.Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
EP1039910A1 (en) * 1997-11-06 2000-10-04 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Also Published As

Publication number Publication date
ES2272305T3 (es) 2007-05-01
CZ2002474A3 (cs) 2003-02-12
EA006876B1 (ru) 2006-04-28
AR029763A1 (es) 2003-07-16
PT1202746E (pt) 2007-01-31
NO20020663D0 (no) 2002-02-11
EP1202746B1 (en) 2006-10-04
AU6395900A (en) 2001-03-13
HUP0203162A2 (hu) 2003-01-28
NO20020663L (no) 2002-04-09
CA2380904C (en) 2009-02-10
IL147913A0 (en) 2002-08-14
EP1202746A1 (en) 2002-05-08
WO2001012227A1 (en) 2001-02-22
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
HUP0203162A3 (en) 2006-07-28
ZA200201156B (en) 2003-05-12
EA200200246A1 (ru) 2002-08-29
ATE341341T1 (de) 2006-10-15
KR20020018201A (ko) 2002-03-07
DK1202746T3 (da) 2007-01-02
PL353267A1 (en) 2003-11-03
CN1229142C (zh) 2005-11-30
BR0013219A (pt) 2002-04-23
DE60031127D1 (de) 2006-11-16
NZ517120A (en) 2004-10-29
CN1370080A (zh) 2002-09-18
JP2003507342A (ja) 2003-02-25
DE60031127T2 (de) 2007-02-01
MXPA02001448A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
HK1042244A1 (zh) 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物
IL151249A0 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
DK1286671T3 (da) Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan
WO2005018677A3 (en) Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
ZA9810134B (en) Method of treating or inhibiting colonic polyps.
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO1998036730A3 (de) Zubereitungen für die behandlung von rosacea
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
WO2003090753A8 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
PL368271A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
AU2001267824A1 (en) Remedies for cancer
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA